Long-term treatment with idebenone and riboflavin in a patient with MELAS.
We report a patient with MELAS treated for 24 months with idebenone and riboflavin, during which no stroke-like episodes occurred. Moreover neurological symptoms clearly improved, and a recovery of brain MRI and EEG abnormalities was observed. We conclude that the combined treatment with idebenone and riboflavin may restore the metabolic impairment in MELAS, possibly improving the long-term prognosis in these patients.
Napolitano
A
A
Division of Neurology, Campo di Marte Hospital, I-55100 Lucca, Italy.
Salvetti
S
S
Vista
M
M
Lombardi
V
V
Siciliano
G
G
Giraldi
C
C
D000328:Adult; D000975:Antioxidants / Q000494:pharmacology*; D001041:Aphasia, Wernicke / Q000188:drug therapy / Q000209:etiology / Q000473:pathology; D016227:Benzoquinones / Q000494:pharmacology*; D002540:Cerebral Cortex / Q000473:pathology / Q000503:physiopathology; D002544:Cerebral Infarction / Q000188:drug therapy / Q000209:etiology / Q000473:pathology; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D004579:Electron Transport / Q000187:drug effects / Q000235:genetics; D006801:Humans; D017241:MELAS Syndrome / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D008279:Magnetic Resonance Imaging; D008297:Male; D008928:Mitochondria / Q000187:drug effects / Q000235:genetics / Q000378:metabolism; D017319:Photosensitizing Agents / Q000494:pharmacology*; D012256:Riboflavin / Q000494:pharmacology*; D016896:Treatment Outcome; D014451:Ubiquinone / Q000031:analogs & derivatives
D000975:Antioxidants; D016227:Benzoquinones; D017319:Photosensitizing Agents; D014451:Ubiquinone; C036619:idebenone; D012256:Riboflavin